Perspective Therapeutics, Inc. CATX
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -66.88% | -57.99% | -39.20% | -30.96% | -15.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.88% | -57.99% | -39.20% | -30.96% | -15.64% |
| Cost of Revenue | 79.26% | 97.06% | 113.59% | 77.72% | 88.98% |
| Gross Profit | -82.70% | -102.14% | -119.44% | -82.80% | -94.67% |
| SG&A Expenses | -4.26% | 2.80% | 13.60% | 35.27% | 47.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.02% | 56.47% | 67.69% | 61.78% | 72.65% |
| Operating Income | -46.64% | -58.70% | -70.01% | -64.28% | -75.30% |
| Income Before Tax | -20.43% | -29.57% | -29.84% | -117.29% | -120.03% |
| Income Tax Expenses | 62.18% | 62.18% | 62.18% | -126.72% | -126.72% |
| Earnings from Continuing Operations | -22.24% | -31.84% | -32.30% | -84.11% | -82.90% |
| Earnings from Discontinued Operations | -56.70% | 205.33% | 154.28% | 107.49% | 106.64% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.62% | -30.48% | -30.07% | -65.87% | -60.89% |
| EBIT | -46.64% | -58.70% | -70.01% | -64.28% | -75.30% |
| EBITDA | -46.78% | -59.53% | -71.04% | -64.42% | -74.67% |
| EPS Basic | -0.51% | -15.55% | -15.72% | 3.89% | 20.91% |
| Normalized Basic EPS | -31.71% | -58.81% | -60.85% | -11.30% | 12.50% |
| EPS Diluted | -0.51% | -15.55% | -15.72% | 3.89% | 20.91% |
| Normalized Diluted EPS | -31.71% | -58.81% | -60.85% | -11.30% | 12.50% |
| Average Basic Shares Outstanding | 29.46% | 16.41% | 14.60% | 35.76% | 67.17% |
| Average Diluted Shares Outstanding | 29.46% | 16.41% | 14.60% | 35.76% | 67.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |